Bagnols-sur-Cèze, France, October 6, 2010: Cisbio Bioassays (www.htrf.com), member of IBA Group and global provider of HTRF® (homogenous time resolved fluorescence) technology and services to facilitate new drug discovery, today announces the signing of a partnership with Blue Sky BioProducts. The combination of TDA 2.0™ technology by Blue Sky BioProducts and HTRF, developed by Cisbio, will enable the development of more robust assays and an unparalleled sensitivity for obtaining better biologically enhanced results on target kinases.
TDA 2.0™ is a stable solution of lipid-based nanoparticles with nickel-chelating moieties. It is a template which directs the assembly of purified His-tagged proteins that are normally membrane-associated, creating a more physiological environment than isolated domains in aqueous buffer. His-tagged proteins bind to the fluid surface of TDA 2.0™ and self-associate as a result of the fluid properties of lipid bilayer. Use of TDA 2.0™ is straightforward and significantly less challenging than traditional membrane reconstitution procedures. Membrane protein assays developed in conjunction with TDA 2.0™ exhibit dramatic increases in enzymatic activity, improved physiological buffer compatibility, and a preference for biologically-relevant substrates.
“Through HTRF, Cisbio Bioassays has developed extensive expertise in the field of kinase enzyme screening tools,” explains François Degorce, director of marketing and communications at Cisbio Bioassays. “The combination of these two proven technologies in this area allows us to provide an even more robust and efficient solution for studying these key therapeutic targets, particularly in oncology research,” he concludes.
The HTRF platform offers a broad choice of reagents and kits for high throughput screening of kinases, whether Tyrosine (Tyr) or Serine/Threonine (Ser/Thr). Thus researchers have a universally-applicable technology for screening and studying major human kinome targets, and an economical solution in terms of implementation and development time.
Furthermore, SmartScreen™ kits containing TDA 2.0™ developed by Blue Sky BioProducts offer a pre-validated, high-quality enzyme, substrate, and reaction buffers that are particularly suitable for HTRF technology.
”Template-directed assembly using TDA 2.0™ is an exciting advancement that provides researchers with a simple tool to develop HTS assays that more closely mimic physiological conditions than can be achieved with isolated catalytic domains,” states Dr. Scott Gridley, director of the BioProducts division at Blue Sky. “Performing assays with membrane associated kinases using TDA 2.0™ in combination with HTRF® detection enables unparalleled results.”
About Blue Sky Biotech, Inc.
Blue Sky Biotech, Inc is an integrated provider of custom biologicals for biomedical research and drug discovery and is organized into two divisions: BioServices and BioProducts. The BioServices division offers a wide range of custom services spanning Molecular Biology, Eukaryotic and Prokaryotic Protein Expression, Protein Purification, and Assay Development. This suite of pre-clinical services provides clients with a convenient source of high quality custom research tools. Blue Sky also invests heavily in technology development to improve or enhance its production capabilities, including a proprietary process technology (IKM®) that significantly reduces cycle times and enhances reproducibility of protein production using baculovirus-mediated insect cell expression. The BioProducts division offers high quality biologicals and membrane protein solutions (TDA™ and SmartScreen™ Kits) designed to facilitate drug discovery. The company is a privately held corporation with over 40 staff members. It is located near Boston, MA, U.S.A. For more information, please visit http://www.blueskybiotech.com.
About Cisbio Bioassays and IBA group
Cisbio Bioassays is a global developer of products and technologies used for in vitro diagnostics and assay development for drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF®, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high throughput screening stage of drug development. In addition, Cisbio Bioassays produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Headquartered in Bagnols-sur-Cèze, France, with facilities in Bedford, MA, U.S.A., and a network of distributors worldwide, Cisbio Bioassays is a member of the Belgium-based IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
Please visit www.htrf.com and www.iba-worldwide.com for more information about Cisbio Bioassays, HTRF technology and IBA.
HTRF® is a trademark of Cisbio Bioassays.
TDA 2.0™ and SmartScreen™ are trademarks of Blue Sky BioProducts.
Christina Aplington / Aline Dubucq
Ballou PR for Cisbio Bioassays
+33 (0)1 42 22 93 65 / +33 (0)1 42 22 97 65
BLUE SKY BIOTECH, INC.